Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) — Market Cap & Net Worth
Market Cap & Net Worth: Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) has a market capitalization of $1.77 Billion ($1.77 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6729 globally and #1977 in its home market, demonstrating a -7.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amylyx Pharmaceuticals Inc's stock price $16.01 by its total outstanding shares 110536944 (110.54 Million). Analyse Amylyx Pharmaceuticals Inc cash conversion from operations to see how efficiently the company converts income to cash.
Amylyx Pharmaceuticals Inc Market Cap History: 2022 to 2026
Amylyx Pharmaceuticals Inc's market capitalization history from 2022 to 2026. Data shows change from $4.08 Billion to $1.77 Billion (-2.77% CAGR).
Index Memberships
Amylyx Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.07% | #173 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #722 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.11% | #111 of 263 |
Weight: Amylyx Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amylyx Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amylyx Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.78x
Amylyx Pharmaceuticals Inc's market cap is 4.78 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $4.08 Billion | $22.23 Million | -$198.38 Million | 183.73x | N/A |
| 2023 | $1.63 Billion | $380.79 Million | $49.27 Million | 4.27x | 33.02x |
| 2024 | $417.83 Million | $87.37 Million | -$301.74 Million | 4.78x | N/A |
Competitor Companies of AMLX by Market Capitalization
Companies near Amylyx Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Amylyx Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Amylyx Pharmaceuticals Inc Historical Marketcap From 2022 to 2026
Between 2022 and today, Amylyx Pharmaceuticals Inc's market cap moved from $4.08 Billion to $ 1.77 Billion, with a yearly change of -2.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.77 Billion | +32.53% |
| 2025 | $1.34 Billion | +219.58% |
| 2024 | $417.83 Million | -74.32% |
| 2023 | $1.63 Billion | -60.16% |
| 2022 | $4.08 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Amylyx Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.77 Billion USD |
| MoneyControl | $1.77 Billion USD |
| MarketWatch | $1.77 Billion USD |
| marketcap.company | $1.77 Billion USD |
| Reuters | $1.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more